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Abstract. Placental alkaline phosphatase (PLAP) is
anchored in the plasma membrane by a
phosphatidylinositol-glycan moiety (PI-glycan). PI-
glycan is added posttranslationally to the nascent pep-
tide chain after the removal of 29 amino acids from
the COOH-terminus. The contribution of selected
COOH-terminal amino acids to the signal for PI-
glycan addition was tested by creating a fusion protein
with the COOH-terminus of PLAP and a secreted pro-
tein and by mutagenesis of specific PLAP 000H-
terminal amino acids. The cDNA encoding the
COOH-terminus of PLAP was fused in frame to the
cDNA for human clotting Factor X and expressed in
transfected COS-1 cells. Fusion proteins containing 32
amino acids of the PLAP COON-terminus were
modified by PI-glycan addition. Thus, the signal for
Pl-glycan modification must reside in these amino
acids . Next, the region between the hydrophobic do-
main and the cleavage site was examined for additional
number of proteins are anchored in the plasma mem-
brane by a COOH-terminal glycosyl phosphatidyl-
inositol moiety (PI-g1Ycan) (Ferguson and Williams,
1988) . cDNA sequences for Pl-glycan-anchored proteins
predict a typical N112-terminal signal peptide that directs
the protein to the ER and a 20-30 amino acid COOH-termi-
nal sequence that is absent in the mature PI-glycan-anchored
membrane proteins. The PI-glycan attachmentoccurs in the
ER shortly after the peptide chainis synthesized, presumably
with the removal of a COOH-terminal peptide (Doering et
al., 1990) . The modified protein is then transported to the
plasma membrane.
The structural determinants that direct the addition of PI-
glycan to proteins are only partially understood. Studies of
decay-accelerating factor (DAF),I Qa-2, and placental alka-
line phosphatase (PLAP) suggest that the signals for PI-
glycan modification reside in or near the COOH-terminal
1. Abbreviations used in thispaper: CRD, cross-reacting determinant; DAF,
decay-accelerating factor; PLAP, placental alkaline phosphatase; VSG,
variable surface glycoprotein.
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determinants. Mutations of the hydrophilic residues in
the spacer region demonstrated that these amino acids
do not contribute to the signal for PI-glycan addition.
Deletion of amino acids in the spacer region prevented
the addition of PI-glycan suggesting that the length of
the spacer domain or the amino acids around the
cleavage site are important determinants. Finally, we
demonstrated that interruption of the hydrophobic do-
main by a charged residue prevents PI-glycan addition
and results in a protein that is secreted into the
medium. The finding that a single Leu to Arg substi-
tution in the hydrophobic domain converts a PI-glycan
anchored, membrane protein to a secreted protein sug-
gests that an essential signal for the correct sorting of
PI-glycan anchored proteins versus secreted proteins
resides in the hydrophobic domain. Substitution of a
charged amino acid for a hydrophobic amino acid may
be a mechanism for producing membrane bound and
secreted forms of the same protein.
peptide that is cleaved (Waneck et al., 1988 ; Berger et al.,
1988; Caras et al., 1989). Comparison of the COON-termi-
nal peptides of PI-glycan linked proteins reveals several
common structural features. Each has a hydrophobic domain
of varying length, but a consensus sequence for this region
is not identifiable. There is a distinct addition site with a pref-
erence for amino acids with small side chains (Micanovic et
al., 1990; Moran et al., 1991). A spacer region containing
hydrophilic and charged amino acids separates the hydro-
phobic domain and the addition site.
The importance ofthe hydrophobic domain has been dem-
onstrated for both DAF and PLAP by analyzing the proteins
expressed in cells transfected with cDNA containing muta-
tions in the hydrophobic domain (Berger et al., 1988; Caras
et al., 1989, 1987) . Truncating or deleting the hydropho-
bic domain prevented the addition of PI-glycan to DAF and
PLAP The hydrophobic domain and 20 additional amino
acids from DAF could be fused to the COON-terminus of
glycoprotein D, a herpes virus-encoded protein, or to human
growth hormone, creating chimeric proteins that were an-
chored in the plasma membrane by PI-glycan (Caras et al.,
7991987). Furthermore, the hydrophobic domain in DAF could
be replaced by other hydrophobic sequences without affect-
ing PI-glycan addition (Caras and Weddell, 1989) . These
studies demonstrate that extensive sequence variation is al-
lowed by the hydrophobic region.
In this study, fusion proteins of human clotting Factor X,
a secreted protein, and varying lengths of the COOH-termi-
nus ofPLAP were constructed to determine if the entire sig-
nal for PI-glycan addition resides in the COON terminus and
to identify the minimum number of amino acids required for
PI-glycan addition. After establishing that the COON-termi-
nal 32 amino acids contain the signal for PI-glycan attach-
ment, various mutations were made in the acceptor amino
acid, Asp484, and in selected spacer region amino acids to
test their contribution to the PI-glycan modification signal.
Finally, a charged amino acid was introduced into the middle
ofthe hydrophobic domain to determine ifa charged residue
can be accommodated within the hydrophobic domain. The
interruption ofthe hydrophobic domain with a charged amino
acid converted PLAP from a membrane-anchored protein to
a secreted protein.
Materials and Methods
Construction ofChimericcDNA and Mutants
The cDNA ofhuman clotting factor X was ligated in frame to synthetic oli-
gonucleotides encoding the 3'-coding region of human PLAP. The Factor
X cDNA was in the Smal site of a pGEM 4z plasmid that had been previ-
ously engineered to replace the KpnI site in the polylinker with an Xhol
site atthe 3' end ofthe cDNA insert (Sims, H. F. and A. W. Strauss, unpub-
lished data). The Factor X plasmid was digested with XhoI and BstEII to
remove 134 by from the 3' end of the plasmid. A synthetic 50-bp double-
strandedoligonucleotide containing by 1,508 to 1,548 ofPLAPandthe Fac-
tor X BstEII site at the 5' end and an XhoI site downstream from the stop
codon (see Fig. 1) was ligated into the plasmid. This oligonucleotide con-
tained a silent, single base mutation that changed by 1,512 from a G to a
T introducing a unique KpnI site. The construct was cleaved at the unique
KpnI site and with BstEII and a second double-stranded oligonucleotide
spanning by 1,460 to 1,514 ofthe PLAP sequence was ligated into the plas-
mid. The three constructs werethen finishedby ligating the appropriatesyn-
thetic oligonucleotides into the Xmal site at by 1,471 and the Factor X
BstEII site (see Fig. 1).
Mutant sequences were introduced into the cDNA encoding PLAP by
cassette mutagenesis. First, the unique KpnI site was introduced into PLAP
by ligating the cDNA encoding the PLAP COOH terminus of the fusion
protein. The Ala477 plasmid was digested with Xbal and NaeI and the plas-
mid containing by 1,441 to the stop codon of PLAP was separated from
the FactorX cDNA by agarose gel electrophoresis and isolated by the Gene-
Clean (Bio 101, La Jolla, CA) method following the manufacturer's direc-
tions. The plasmid containing the PLAP cDNA was digested with XbaI at
the 5' end and StuI at by 1,160. Another aliquot ofthe plasmid was digested
with Stul and NaeI to give three fragments, a larger one containing pGEM
and a portionofthe PLAP cDNA, a688-bp NaeI/StuI fragment, and a281-
bp StuI/NaeI fragment. The 281-bp StuI/NaeIand 1,160-bp XbaI/StuI frag-
ments were isolated from agarose gels by the Gene Clean method. The
previously digested plasmid containing the 3' end ofthe PLAP cDNA, the
281-bp fragment, and the 1,160-bp piece were ligated together to create a
plasmid with a 1,550-bp insert containing the entire coding region ofPLAP
and the unique KpnI site.
The nucleotide sequence ofall constructswas verified by dideoxynucleo-
tide sequence analysis (Sanger et al ., 1977). All manipulations of DNA
were accomplished by standard methods (Sambrook et al., 1989).
Ransfections andAnalysis ofRecombinant Proteins
The cDNA constructs were subcloned into the pSVL expression vector.
COS 1 cells were transfected with DEAE-dextran, labeled with 1355]me-
thionine, and the expressed proteinspurified with rabbit anti-human PLAP
or Factor X antibodies as previously described (Lowe and Strauss, 1990).
Phospholipase C digestion, SDS-PAGE and immunoblots were done as be-
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fore (Lowe and Strauss, 1990) . The antibody to the trypanosoma variable
surface glycoprotein cross-reactingdeterminant (anti-CRD) was agift from
A. Gurnett and M. Turner ofMerck, Sharp, and Dohme (West Point, PA).
For glycosidase treatment, immunopurified proteins were eluted from
protein-A Sepharose by boiling for 3 min in 10 p,l 0.5% SDS and 0.1 M
R-mercaptoethanol. For glycosidase F digestion, 11.0 pl 0.55 M sodium
phosphate, pH 8.6, 5.0 pl 7.5% NP-40, 3 Al H2O, and 300 mU of N-gly-
canase (Genzyme, Boston, MA) were added and the sample incubated un-
der toluene at 37°C for overnight. For endoglycosidase H digestion, 0.25 M
sodium phosphate, pH 5.5, and 50 mU endoglycosidase H (Boehringer-
Mannheim Biochemicals, Indianapolis, IN) replaced the corresponding
components listed above.
Immunofluorescence ofRansfected Cells
COS-1 cells were grown to 30-50% confluence on cover slips and trans-
fected with the desired plasmids. After 48-60 h, the medium was aspirated
and the cover slips washed three times with PBS. The cells were fixed for
5 min with 4% formaldehyde in cold PBS for surface labeling or with ice-
cold acetone forpermeabilizedcells. The fixative was aspirated andwashed
away with cold PBS. The cells were then incubated with 1% BSA in 10 mM
Tris-HCl, pH 8.0, 0.9% NaCI for 1 h followed by the primary rabbit anti-
body diluted in 1% BSA, 0.3% gelatin, 25 mM NaP04, pH 7.5, 0.9%
NaCl for 1 hat room temperature. Theunbound antibody was washed from
the cells with PBS and a fluorescein-conjugated goat anti-rabbit IgG (Vec-
tor Laboratories, Inc., Burlingame, CA) was added in the same buffer as
the primary antibody. After 1 h, the cover slip was washed with PBS and
mounted in 50% glycerol in PBS.
Results
Expression ofPLAP and Factor X Chimeric Proteins
in COS 1 Cells
Initially, two fusion proteins were tested. Ala477 had the
COOH-terminal 37 amino acids of PLAP attached to 455
amino acids ofFactor X. Thr482 contained the last 32 amino
acids of PLAP ligated to Factor X (Fig. 1). Both fusion pro-
teins contained the PI-glycan acceptor site Asp484. Wild
type PLAP, Factor X, and the two fusion cDNAs were trans-
fected into COS 1 cellsto determine the fate ofthe expressed
proteins. The cells were labeled with [35S]methionine and
the immunopurified proteins were analyzed by SDS-PAGE
and autoradiography. All four proteins were made in similar
quantities by the COS 1 cells and were present in the cell pel-
let (Fig. 2) .
PLAP was detected as two bands in the cell pellet. There
was no PLAP present in the medium. In contrast, wild type
Factor X was secreted into the medium in significant
amounts with only a smallamount retained in the cell pellet.
The majority of the Factor X was present in the medium as
the mature single-chain protein. Factor X is normally
processed by a protease into a heavy and light chain and
these were also detected in the medium (Leytus et al., 1986) .
Both Ala477 or Thr482 were detected only in the cell pellet,
and like PLAP, migrated as two bands. Neither was secreted
by the cells into the medium and there were no detectable
processing products. Thus, Ala477 and Thr482 are cell as-
sociated and present either on the cell surface or in the
cytoplasm.
Cellular Location of the Fusion Proteins
To determine if the fusion proteins were present on the cell
surface, transfected cells were analyzed by indirect im-
munofluorescence. Surface labeling of intact, transfected
cells with specific antibodies demonstrated that PLAP and
the chimerics were expressed on the cell surface (Fig. 3) . In
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Amino Acid Sequence of the Chimeric Proteins
443 450
arkgkygiytkvtAPPAGTTDAAHPGRSVVPALLPLLAGTLLLLETATAP Ala477
477 485 495 505
arkgkygiytkvtTTDAAHPGRSVVPALLPLLAGTLLLLETATAP Thr482
482 490 500 510
arkgkygiytkvtAAHPGRSVVPALLPLLAGTLLLLETATAP Ala485
485 495 505
Figure 1 . The construction and amino acid sequence ofcDNAs en-
coding Factor X and PLAP fusion protein . A shows the schematic
diagram of the Factor X/PLAP chimeric cDNA . 1,366 by out of
1,467 by in complete Factor X cDNA was fused to the nucleotide
sequence encoding the COOH-terminal of PLAP The unique re-
striction sites are shown : B, BStElI ; S, SmaI or XmaI ; K, Kpnl ; X,
XhoI . The number ofbase pairs for the Factor XcDNA are shown
above the line . The numbers for thePLAPcDNA are shown below .
B shows the amino acid sequence for the three constructs using the
single letter code . The amino acids derived from Factor X are in
lower case . The amino acids from PLAP are in upper case . The
numbers above the line are the amino acid position for Factor X .
Those numbers below the line are for PLAP The aspartic acid ac-
ceptor is indicated by an asterisk .
Figure2. The expression ofwild type PLAP, Factor X, Ala477, and
Thr482 in COS-1 cells . COS-1 cells were transfected with cDNA,
labeled for 2 h with ['SS]methionine, and the expressed protein
purified from the cells and from the medium by immunoprecipita-
tion with specific antibodies. The cell pellet was lysed in Triton
X-100 and deoxycholate-containing buffer and treated with PI-PLC
in this experiment . The products were analyzed by SDS-PAGE and
autoradiography after transfer to Immobilon P membrane .
Lowe Signal for Phosphatidylinositol-glycan Addition
contrast, Factor X was not detected on intact cells, but was
readily located inside the cells after disruption of the cell
membrane with acetone. Although Ala477 and Thr482 are
clearly on the cell surface, the mechanism of anchoring the
proteins in the cell membrane can not be determined by im-
munofluorescence .
PIglycan Addition to the Fusion Proteins
Initial experiments showed that PLAP was readily removed
from the COS 1 cells by PI-PLC, but that only a small per-
centage of Ala477 and Thr482 were removed by PI-PLC
(data not shown) . Therefore, other approaches were used to
demonstrate the presence of the PI-glycan moiety on the fu-
sion proteins . First, the cells were metabolically labeled
with [3H]ethanolamine, a component of PI-glycan (Doering
et al ., 1990) . PLAP, Ala477, and Thr482, but not Factor X,
labeled with ethanolamine (Fig . 4) . FactorX in the medium
was also not labeled (data not shown) . The presence of
ethanolamine in Ala477 and Thr482 suggests that both con-
tain the PI-glycan moiety.
Further evidence for the presence of PI-glycan on the fu-
sion proteins was obtained by testing for binding to an anti-
body raised against the trypanosoma variable surface glyco-
protein (VSG) . This antibody (anti-CRD) reacts primarily
with the inositol-phosphate that is exposed in PI-glycan after
treatment with PI-PLC (Shak et al., 1988) . The cell pellets
were extracted with buffer containing deoxycholate and Tri-
ton X-100 and the cell lysates were treated withPI-PLC . The
PI-PLC-treated proteins were purified by immunoprecipita-
tion . [35S]methionine-labeled PLAP, Ala477, and Thr482
migrated as two bands detected by fluorography. Wild type
PLAP, Ala477, and Thr482 bound the anti-CRD antibody
(Fig . 5) . Ala477 and Thr482 that had not been treated with
PI-PLC did not bind the anti-CRD antibody. Factor X also
did not bind the antibody. In sum, these results-the location
on the cell surface, labeling with ethanolamine, and binding
to anti-CRD-demonstrate that the fusion proteins contain
sufficient information to signal PI-glycan addition and to di-
rect a secreted protein to the plasma membrane .
Importance ofthe Addition Site in Directing
PI-glycan Addition
Both Ala477 and Thr482 contain the PI-glycan addition site,
Asp484 . To determine if the sequence distal to this site con-
tained the signal for PI-glycan addition a third construct
(designated Ala485 in Fig . 1) was tested . This construct in-
cluded the 31 amino acids distal to Asp484, but not Asp484 .
The expressed protein was present in the cell pellet and not
in the medium (Fig . 6 A, lanes 1 and 2) . There was no detect-
able release of the protein into the medium by PI-PLC (Fig.
6 A, lanes 3 and 5) and the anti-CRD antibody did not bind
to the PI-PLC-treated protein (Fig . 6 A, lane 5) . Addition-
ally, the protein was not detected on the cell surface by im-
munofluorescence on intact cells, but was easily detected in
permeabilized cells (Fig . 6 B) . Thus, the COOH-terminal
amino acids adjacent to Asp484 do not, by themselves, allow
PI-glycan addition in this fusion protein . A suitable acceptor
amino acid, Asp484 forPLAP, must also be present . The ab-
sence of a complete signal for PI-glycan addition led to
retention inside the cell .
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Figure 4. Labeling of the expressed
proteinswithethanolamine .Thetrans-
fected COS-1 cells were labeled with
13H]ethanolamine for 8 h and the ex-
pressed proteins in the cell pellet
purified with specific antibody. The
proteins were analyzed by SDS-PAGE
andfluorography. Lane 1 shows wild
type PLAP Lane 2 shows wild type
FactorX. Lane3contains the Ala477
chimera and lane 4 has the Thr482
chimeric protein.
Figure 3 Detection of the expressed proteins by
immunofluorescence . Transfected cells were fixed
andincubatedwith specific antibodies to PLAP or
Factor X (wild type and chimerics) . Binding of
theantibody was detected witha fluorescein-conju-
gated goat anti-rabbit antibody. No fluorescence
was detected when the cells transfected with wild
type PLAP were incubated with the anti-FactorX
antibody or when the Factor X transfected cells
were incubated with anti-PLAP antibody.
The Effect ofMutations in theCOOH Terminus of
PLAP on PIglycan Addition
Becauseof the possibility that Factor X may contain signals
for secretion that would complicate the analysis ofmutations
in thePLAP COOH terminus, further analysis oftheCOOH
terminus wasdone by introducing a varietyofmutations into
PLAP by cassette mutagenesis . Changes were made in the
spacer region, theaddition site, and thehydrophobic region .
To test the contribution of the hydrophilic residues in the
spacer region to the signal for PI-glycan addition, we
changedH487, R490, and S491 to a leucine alone or in com-
bination . The effect of increased charge in the spacer domain
wastested by changing H487 to an arginine.A deletion mu-
802Figure 5. Binding of PLAP,
Factor X, Ala477, and Thr482
tothe Anti-CRD antibody. The
cell pellets from transfected
cells were lysed in TritonX-100
and deoxycholate containing
detergent and treated for 1 h at
37°C with PI-PLC . The un
treated cell pellets were incubated without PI-PLC under identical conditions . The proteins were separated by SDS-PAGE and transferred
to Immobilon P membrane. Radiography was done to detect the ['SS]methionine-labeled protein and the presence of PI-glycan determined
by binding of the anti-CRD antibody. The primary antibody was detected with an alkaline phosphatase conjugated goat anti-rabbit antibody.
The PI-plc-treated samples are the same ones shown in Fig . 2 .
tant was created in the spacer region to determine the impor-
tance of the amino acids adjacent to the PI-glycan acceptor
site . The effects of charge, side group size, and polarity at
the position of the acceptor amino acid, D484, were exam-
ined by mutations at that site . Finally, a charged residue was
introduced into the middle of the hydrophobic domain to de-
termine if the hydrophobic stretch could be interrupted by a
charged residue as can occur in the membrane domain of a
transmembrane protein (Engelman et al ., 1986) . Each mu-
tant was tested by transfection intoCOS 1 cells and the pres-
ence of PI-glycan determined by susceptibility to PI-PLC
cleavage .
As shown by [ 35S]methionine labeling, all of the mutant
proteins were expressed by the transfected cells (Fig . 7 A) .
Two bands were present for some of the mutants and only
one band, the faster migrating band, was present for other
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mutants . Pulse chase experiments with the wild type showed
that the faster migrating band was detected initially and that
both bands were present at later time points (Fig . 8) . After
labeling with ["S]methionine for 2 h and treating with
glycopeptidase F, PLAP was present as a single band of
lower apparent molecular weight than the two untreated
bands . Furthermore, endoglycosidase H treatment ofPLAP
labeled for 10 min produced a single band ofthe same mobil-
ity as the glycopeptidase F-treated PLAP. The differences
between the two forms ofPLAP is a result ofoligosaccharide
processing . The lower band contains high-mannose oligo-
saccharides and is presumably located in the ER .
Only the Leu500 to Arg500 mutant was present in the
medium . Thus, the introduction of a single charged amino
acid in the middle of the hydrophobic domain resulted in
secretion of that protein (Fig . 7 B) . The secreted proteinwas
803
Figure 6. The expression of Ala485 in COS-1
cells and the cellular location of the protein . A
shows the analysis of the protein purified from
['SS]methionine labeled, transfected COS-1
cells by specific antibodies . Lanes 1 and 3 show
the cell pellet . Lanes 2 and 4 show the medium .
The material in lanes 3 and 4 was from cells
treated with PI-PLC. Lane 5 shows the immu-
noblot of the PI-PLC-treated protein with the
anti-CRD antibody. B shows the location ofthe
fusion protein in the cells by immunofluores-
cence. Surface indicates that intact cells were
incubated with antibody. Permeable indicates
that the cell membrane was disrupted with ace-
tone before incubation with antibody.Figure 7 . The expression ofPLAP mutants in COS-1 cells . Transfected COS-1 cells were labeled with ["S]methionine for 2 h and purified
with anti-PLAP antibody . The proteins were analyzed by SDS-PAGE and fluorography. A shows the protein in the cell pellet and B shows
the protein inthe growth medium . The wild type amino acid is given above the line and the mutant amino acids below the line . The000H-
terminal amino acids for wild type PLAP are given below. Positions of the changes are marked . The amino acids deleted are underlined .
Figure 8. Pulse-chase and endoglycosidase treatment ofPLAP The
results of treating PLAP with glycopeptidase F or endoglycosidase
H and of a pulse chase are shown here. The transfected cells were
labeled with [35S]methionine for 2 h before immunopurification
and treatment with glycosidase F. For the pulse-chase and en-
doglycosidase H experiments the cells were labeled for 10 min. The
chase was done with 500x cold methionine in the medium . The
chase times are indicated in the figure . Lane 1, glycosidase
F-treated PLAP Lane 2, endoglycosidase H-treated PLAP Lanes
3-7, pulse chase of PLAP.
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also larger than the membrane-bound forms, 69 versus 64
kD, suggesting that the secreted form is processed differently
from the membrane-bound form . The secreted PLAP had
phophatase activity. Approximately 400 mU ofAP activity
per 100 mm culture dish was present in the medium of the
cells transfected with the Arg500 mutant but there was no
detectable activity in the medium from cells transfected with
wild type or other mutant PLAPs . The results suggest that
the Arg500 mutant is not modified by PI-glycan and under-
scores the importance of an uninterrupted hydrophobic do-
main for PI-glycan addition .
The presence of PI-glycan was determined by release of
the various proteins into the medium after treatment with PI-
PLC (Fig . 9) . Wild type PLAP was readily released into the
medium by PI-PLC. Only one of the three acceptor site mu-
tants, Va1484 for Asp484, was cleaved by PI-PLC indicating
that valine can support PI-glycan addition (Fig. 9, D484) .
The introduction of the opposite charge, lysine, or ofa bulk-
ier but identically charged amino acid, glutamic acid,
blocked the addition of PI-glycan .
The only construct with a mutation in the hydrophobic do-
main was Arg500 for Leu500. Although most of the mutant
protein was found in the medium after transfection and was
not modified by PI-glycan, there was PLAP associated with
the cell pellet, and some of this protein may contain PI-
glycan . The cell-associatedPLAP8500 was not released by
PI-PLC, confirming that PLAP8500 is not a suitable accep-
tor for PI-glycan (Fig . 9, LS00) .
Proteins that are modified with PI-glycan have hydrophilic
804Figure 9 The release of PLAP mutants by PI-PLC . Cells were transfected and labeled with [31S]methionine for 2 h as described in
Materials and Methods . The intact cells were treated with PI-PLC for 1 h at 37°C . The PLAP was purified with specific antibodies and
separated by SDS-PAGE . A shows the protein remaining with the cell pellet . B shows the protein released into the medium by PI-PLC.
The wild type amino acids are given above the line andthe mutants below the line . The COOH-terminal acids ofPLAP are givenbelow.
amino acids in the spacer region between the hydrophobic
domain and the acceptor site (Ferguson and Williams,
1988) . Each of the hydrophilic residues in the PLAP spacer
region, His487, Arg490, and Ser491, was replaced with leu-
cine individually and in combinations (Fig . 9) . None of the
mutations abolished the cleavage by PI-PLC. Additionally,
increasing the charge of the spacer domain by changing
His487 to a charged residue, arginine, had no effect on PI-
Table I . Sequence ofthe COOH Terminus ofthePLAPMutants and Their Location by Indirect Immunofluorescence
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PLC cleavage. These results suggest that hydrophilic or
chargedresidues in the region between the addition site and
the hydrophobic core are not critical forPI-glycan addition .
In contrast, deletion of three amino acids in the spacer re-
gion from Ala485 to His487 blocked release into the
medium by PI-PLC . The deletion apparently prevented PI-
glycan addition to themutant protein . Either theaminoacids
immediately distal to the cleavage site contribute to the
The last 37 residues of theCOOH terminus of PLAP are shown using the single letter amino acid code. The acceptor site is Asp484 . Only the substituted amino
acids are given for the mutants. The --- signifies a deletion at that site . The location of the expressed protein in COS-1 cells by indirect immunofluorescence is
indicated. Surface means immunofluorescence was detected on the surface of intact cells . Intracellular means that the protein was detected only after disrupting
the cell membrane as described in Methods .
Mutant Amino acid sequence Location
484 490 500 510
Wild type . . .APPAGTTDAAHPGRSVVPALLPLLAGTLLLLETATAP Surface
Glu484 E Intracellular
Lys484 K Intracellular
Va1484 V Surface
Leu487 L Surface
Arg487 R Surface
Leu490 L Surface
Leu491 L Surface
Leu490,491 LL Surface
Leu487,490,491 L LL Surface
De1485-487 -- - Intracellular
Arg500 R Intracellularspecificity of cleavage or the distance between the cleavage
site and the hydrophobic domain is important. In this mu-
tant, a proline is placed next to the acceptor aspartic acid.
The bulky side chain or helix-breaking properties of proline
could prevent cleavage between the aspartic acid and proline.
The location of the expressed proteins was confirmed by
indirect immunofluorescence of transfected cells (Table I) .
The immunofluorescence is consistent with the location of
the mutants as determined by PI-PLC susceptibility. As
found by others, substitutions that block PI-glycan addition
also abolish transport to the cell surface. The proteins ac-
cumulate in cytoplasmic compartments (Moran et al ., 1991) .
The Leu500 to Arg500 is the first exception to this general
finding.
Discussion
Work with DAF and human growth hormone chimerics sug-
gests that all of the information for PI-glycan addition is con-
tained in the COOH-terminus of DAF (Caras et al., 1989) .
The location of the signals for PI-glycan addition in PLAP
was determined by creating chimerics of human Factor X
and various portions ofthe COOH terminus of PLAP Factor
X is normally a secreted protein and the precursor contains
the signals necessary to enter the ER lumen where PI-glycan
modification occurs. Furthermore, Factor X does not have
a membrane-bound form and should not contain other sig-
nals that might direct the protein to the plasma membrane.
Thus, the signal directing any of the Factor X-PLAP fusion
proteins to the cell surface would be present in the PLAP-
derived amino acids. The information for PI-glycan addition
was found to reside in the 32 COOH-terminal amino acids
containing the addition site and the intact hydrophobic do-
main. The information present in these amino acids con-
verted a secreted protein, Factor X, into a membrane-bound
protein.
The COOH-terminal peptide contains an essential hydro-
phobic domain and a cleavage/attachment site separated by
a spacer region. Mutation of the hydrophilic residues in the
spacer domain to hydrophobic residues either alone or in
combination did not abolish the addition of PI-glycan . Even
though all of the PI-glycan-containing proteins have hydro-
philic residues in the spacer region, these results demon-
strate that their presence is not required for PI-glycan ad-
dition. Alternatively, the distance between the hydrophobic
domain and the cleavage site may be crucial.
The spacer domain in PLAP was shortened by deleting
three amino acids immediately COOH-terminal to the addi-
tion site, leaving only four amino acids in the spacer domain .
This mutant remained inside the cell . Caras and colleagues
made deletions in DAF that shortened the spacer domain
(Caras et al ., 1989). Even a mutant missing the normal at-
tachment site was modified by PI-glycan presumably at an
alternative site within 8 to 15 residues of the hydrophobic do-
main. The Ala485 chimeric has a valine 9 residues from the
hydrophobic domain and a glycine 14 residues upstream, but
neither of these sites is used. Similarly, the DAF and human
growth hormone chimeric reported by Moran and co-
workers has suitable amino acids 11 and 13 residues NH3-
terminal to the hydrophobic domain and is not modified by
PI-glycan (Moran et al., 1991) . These results suggest that
more than distance from the hydrophobic domain is impor-
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tant in determining the PI-glycan addition site. The addition
may also be affected by the residues around the addition site.
Thus, the proline nextto Asp484 in the PLAP deletion mutant
may prevent cleavage or modification. Residues immediately
COOH-terminal to the addition site may also be crucial. Lys,
Cys, Gly, Ala, Arg, and Thr are located next to the addition
site in the proteins where the amino acid sequence is known
(Ferguson and Williams, 1988; Moran et al., 1991).
The importance of an uninterrupted COOH-terminal hy-
drophobic domain is illustrated in our studies by introducing
a charged amino acid into the middle of the hydrophobic re-
gion. Surprisingly, the Leu500 to Arg500 mutant was not
PI-glycan modified or sequestered inside the cell, but was
secreted into the medium. Single amino acid changes in
Qa-2 and the CD16 IgG Fc receptor converted a PI-glycan-
linked protein to a transmembrane protein and truncation of
the hydrophobic domain of PLAP produced a secreted pro-
tein, but no other single amino acid changes are known to
convert a PI-glycan-linked protein to a secreted protein (Wa-
neck et al., 1988; Lanier, et al., 1989; Kurosaki and Ra-
vetch, 1989). This finding raises the possibility that AP
found in the serum may be a secreted form of the protein
rather than a phospholipase cleavage product of cell sur-
face AP
Other mutations in PLAP and DAF that prevent PI-glycan
addition result in the accumulation of the mutant protein in-
side the cell, presumably within the ER or Golgi complex
(Cara et al., 1989 ; Micanovic et al., 1990; Lodish, 1988) .
The mechanism for retention is not clear, but improper fold-
ing of the mutant proteins has been proposed as a possibility.
Alternatively, changes that affect the cleavage/attachment
site may produce proteins that are anchored in the ER mem-
brane and unable to proceed because the PI-glycan moiety
is essential for proper targeting. These proteins would also
lack the intracytoplasmic domain that may be necessary to
route transmembrane proteins to the cell surface. This mech-
anism predicts that specific sorting of membrane proteins oc-
curs in the ER and that proteins lacking the correct signals
are retained in the ER. The leucine to arginine mutation
would circumvent the membrane pathway by preventing the
nascent peptide chain from anchoring in the ER membrane.
Instead, the mutant protein enters the ER lumen and follows
the pathway for secreted proteins.
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